EUVIMEDEUVIMED entdecken
Open Access

Hepatic ZBTB22 promotes hyperglycemia and insulin resistance via PEPCK1‐driven gluconeogenesis

Naihua Liu iD, Xiaoying Yang iD, Jingyi Guo, Lei Zhang, Shangyi Huang, Jiabing Chen, Jiawen Huang, Yingjian Chen, Tianqi Cui, Yi Zheng iD, Tianyao Li, Kaijia Tang und 7 weitere

EMBO Reports · 05.06.2023 · 24 (6)

DOI: 10.15252/embr.202256390 ↗

Kurz gefasst

Fachartikel in der Zeitschrift EMBO Reports, online erschienen am 08.05.2023. Verfasst von Naihua Liu und 18 weiteren Autor:innen. Beteiligte Einrichtung: Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China. Hauptthemen laut MEDLINE: Insulin Resistance, Glucose Intolerance, Hyperglycemia, Fatty Liver. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Discipline Collaborative Innovation Team of Guangzhou University of Traditional Chinese Medicine, Guangdong Basic and Applied Basic Research Foundation, Guangzhou Science and Technology Planning Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Excessive gluconeogenesis can lead to hyperglycemia and diabetes through as yet incompletely understood mechanisms. Herein, we show that hepatic ZBTB22 expression is increased in both diabetic clinical samples and mice, being affected by nutritional status and hormones. Hepatic ZBTB22 overexpression increases the expression of gluconeogenic and lipogenic genes, heightening glucose output and lipids accumulation in mouse primary hepatocytes (MPHs), while ZBTB22 knockdown elicits opposite effects. Hepatic ZBTB22 overexpression induces glucose intolerance and insulin resistance, accompanied by moderate hepatosteatosis, while ZBTB22-deficient mice display improved energy expenditure, glucose tolerance, and insulin sensitivity, and reduced hepatic steatosis. Moreover, hepatic ZBTB22 knockout beneficially regulates gluconeogenic and lipogenic genes, thereby alleviating glucose intolerance, insulin resistance, and liver steatosis in db/db mice. ZBTB22 directly binds to the promoter region of PCK1 to enhance its expression and increase gluconeogenesis. PCK1 silencing markedly abolishes the effects of ZBTB22 overexpression on glucose and lipid metabolism in both MPHs and mice, along with the corresponding changes in gene expression. In conclusion, targeting hepatic ZBTB22/PEPCK1 provides a potential therapeutic approach for diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Insulin ResistanceGlucose IntoleranceHyperglycemiaFatty LiverMiceAnimalsGluconeogenesisLiverGlucoseMice, Inbred C57BLHepatocytes

Stichwörter der Autor:innen

PEPCK1ZBTB22gluconeogenesishepatosteatosishyperglycemia

Substanzen

Glucose

Autor:innen und Institutionen

  • Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
  • Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine in Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, Jiangsu Province, China.
  • Jiangsu Key Laboratory of Immunity and Metabolism, Department of Pathogen Biology and Immunology, Xuzhou Medical University, Xuzhou, China.
  • Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, China.
  • Department of Hepatology, TCM-Integrated Hospital of Southern Medical University, Guangzhou, China.

ORCID-Profile: Naihua Liu, Xiaoying Yang, Yi Zheng, Lili Yu, Dayong Zheng, Yong Gao

Förderung

  • Discipline Collaborative Innovation Team of Guangzhou University of Traditional Chinese Medicine
  • Guangdong Basic and Applied Basic Research Foundation
  • Guangzhou Science and Technology Planning Project
  • Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine
  • Key projects of Guangdong Provincial Department of Education
  • MOST | National Natural Science Foundation of China
  • National Key Clinical Specialty Construction Project (Clinical Pharmacy) and High Level Clinical Key Specialty (Clinical Pharmacy) in Guangdong Province
  • Natural Science Foundation of Guangdong Province

Zitieren

APA

Liu, N., Yang, X., Guo, J., Zhang, L., Huang, S., Chen, J., Huang, J., Chen, Y., Cui, T., Zheng, Y., Li, T., Tang, K., Zhong, Y., Duan, S., Yu, L., Tang, Y., Zheng, D., Pan, H., & Gao, Y. (2023). Hepatic ZBTB22 promotes hyperglycemia and insulin resistance via PEPCK1‐driven gluconeogenesis. EMBO Reports, 24(6). https://doi.org/10.15252/embr.202256390

Vancouver

Liu N, Yang X, Guo J, Zhang L, Huang S, Chen J, et al. Hepatic ZBTB22 promotes hyperglycemia and insulin resistance via PEPCK1‐driven gluconeogenesis. EMBO Reports. 2023;24(6). doi:10.15252/embr.202256390

BibTeX
@article{Liu2023,
  author = {Liu, Naihua and Yang, Xiaoying and Guo, Jingyi and Zhang, Lei and Huang, Shangyi and Chen, Jiabing and Huang, Jiawen and Chen, Yingjian and Cui, Tianqi and Zheng, Yi and Li, Tianyao and Tang, Kaijia and Zhong, Yadi and Duan, Siwei and Yu, Lili and Tang, Ying and Zheng, Dayong and Pan, Huafeng and Gao, Yong},
  title = {Hepatic ZBTB22 promotes hyperglycemia and insulin resistance via PEPCK1‐driven gluconeogenesis},
  journal = {EMBO Reports},
  year = {2023},
  volume = {24},
  number = {6},
  doi = {10.15252/embr.202256390}
}
Kostenlos starten →